CONTEXT: Most papillary thyroid microcarcinomas (PTMCs; ≤ 1 cm diameter) are indolent low-risk tumors, but some cases behave more aggressively. Controversies have thus arisen over the optimum postoperative surveillance of PTMC patients. OBJECTIVES: We tested the hypothesis that clinical criteria could be used to identify PTMC patients with very low mortality/recurrence risks and attempted to define the best strategy for their management and long-term surveillance. DESIGN: We retrospectively analyzed data from 312 consecutively diagnosed PTMC patients with T1N0M0 stage disease, no family history of thyroid cancer, no history of head-neck irradiation, unifocal PTMC, no extracapsular involvement, and classic papillary histotypes. Additional inclusion criteria were complete follow-up data from surgery to at least 5 yr after diagnosis. All 312 had undergone (near) total thyroidectomy [with radioactive iodine (RAI) remnant ablation in 137 (44%) - RAI group] and were followed up yearly with cervical ultrasonography and serum thyroglobulin, TSH, and thyroglobulin antibody assays. RESULTS: During follow-up (5-23 yr, median 6.7 yr), there were no deaths due to thyroid cancer or reoperations. The first (6-12 months after surgery) and last postoperative cervical sonograms were negative in all cases. Final serum thyroglobulin levels were undetectable (<1 ng/ml) in all RAI patients and almost all (93%) of non-RAI patients. CONCLUSION: Accurate risk stratification can allow safe follow-up of most PTMC patients with a less intensive, more cost-effective protocol. Cervical ultrasonography is the mainstay of this protocol, and negative findings at the first postoperative examination are highly predictive of positive outcomes.
CONTEXT: Most papillary thyroid microcarcinomas (PTMCs; ≤ 1 cm diameter) are indolent low-risk tumors, but some cases behave more aggressively. Controversies have thus arisen over the optimum postoperative surveillance of PTMC patients. OBJECTIVES: We tested the hypothesis that clinical criteria could be used to identify PTMC patients with very low mortality/recurrence risks and attempted to define the best strategy for their management and long-term surveillance. DESIGN: We retrospectively analyzed data from 312 consecutively diagnosed PTMC patients with T1N0M0 stage disease, no family history of thyroid cancer, no history of head-neck irradiation, unifocal PTMC, no extracapsular involvement, and classic papillary histotypes. Additional inclusion criteria were complete follow-up data from surgery to at least 5 yr after diagnosis. All 312 had undergone (near) total thyroidectomy [with radioactive iodine (RAI) remnant ablation in 137 (44%) - RAI group] and were followed up yearly with cervical ultrasonography and serum thyroglobulin, TSH, and thyroglobulin antibody assays. RESULTS: During follow-up (5-23 yr, median 6.7 yr), there were no deaths due to thyroid cancer or reoperations. The first (6-12 months after surgery) and last postoperative cervical sonograms were negative in all cases. Final serum thyroglobulin levels were undetectable (<1 ng/ml) in all RAIpatients and almost all (93%) of non-RAIpatients. CONCLUSION: Accurate risk stratification can allow safe follow-up of most PTMC patients with a less intensive, more cost-effective protocol. Cervical ultrasonography is the mainstay of this protocol, and negative findings at the first postoperative examination are highly predictive of positive outcomes.
Authors: Aubrey A Carhill; Danielle R Litofsky; Douglas S Ross; Jacqueline Jonklaas; David S Cooper; James D Brierley; Paul W Ladenson; Kenneth B Ain; Henry G Fein; Bryan R Haugen; James Magner; Monica C Skarulis; David L Steward; Mingxhao Xing; Harry R Maxon; Steven I Sherman Journal: J Clin Endocrinol Metab Date: 2015-07-14 Impact factor: 5.958
Authors: Megan R Haymart; Mousumi Banerjee; Di Yang; Andrew K Stewart; James C Sisson; Ronald J Koenig; Gerard M Doherty; Jennifer J Griggs Journal: J Clin Endocrinol Metab Date: 2013-03-28 Impact factor: 5.958
Authors: Laura Y Wang; Benjamin R Roman; Jocelyn C Migliacci; Frank L Palmer; R Michael Tuttle; Ashok R Shaha; Jatin P Shah; Snehal G Patel; Ian Ganly Journal: Cancer Date: 2015-08-17 Impact factor: 6.860
Authors: Laura Y Wang; Benjamin R Roman; Frank L Palmer; R Michael Tuttle; Ashok R Shaha; Jatin P Shah; Snehal G Patel; Ian Ganly Journal: Surgery Date: 2015-12-31 Impact factor: 3.982